In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Helius Medical Technologies (HSDT – Research Report). The company’s shares closed yesterday at $5.62.
According to TipRanks, Vendetti is an analyst with an average return of -4.9% and a 32.39% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Biolase, Sensus Healthcare, and Electrocore.
Currently, the analyst consensus on Helius Medical Technologies is a Moderate Buy with an average price target of $24.00.
HSDT market cap is currently $4.99M and has a P/E ratio of -0.39.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Helius Medical Technologies (HSDT) Company Description:
Helius Medical Technologies, Inc. operates as a medical technology company, which engages in the development of products for the treatment of neurological symptoms caused by disease and trauma. It focuses on licensing and acquiring platform technologies that amplify the brain’s ability to heal itself. The company was founded in 2014 and is headquartered in Newtown, PA.
Read More on HSDT:
- Helius Medical reports Q4 EPS ($1.47), consensus ($3.77)
- Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
- Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
- Helius Medical initiates open-label study for registrational program in stroke
- Is HSDT a Buy, Before Earnings?
